

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2019 Army **Date:** February 2018

Appropriation/Budget Activity 2040: Research, Development, Test & Evaluation, Army / BA 5: System Development & Demonstration (SDD)					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev							
COST (\$ in Millions)	Prior Years	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total	FY 2020	FY 2021	FY 2022	FY 2023	Cost To Complete	Total Cost
Total Program Element	-	36.237	39.238	44.542	-	44.542	48.665	50.022	49.735	57.298	0.000	325.737
812: Mil HIV Vac&Drug Dev	-	0.876	1.183	1.179	-	1.179	1.201	1.230	1.067	6.069	0.000	12.805
832: Field Medical Systems Engineering Development	-	19.733	24.812	28.852	-	28.852	31.484	32.382	31.788	34.048	0.000	203.099
849: Infec Dis Drug/Vacc Ed	-	15.520	13.243	14.511	-	14.511	15.980	16.410	16.880	17.181	0.000	109.725
VS8: MEDEVAC Mission Equipment Package (MEP) - End Dev	-	0.108	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	0.108

A. Mission Description and Budget Item Justification

This Program Element (PE) funds advanced development of medical materiel within the System Demonstration and Low Rate Initial Production portions of the acquisition life cycle using 6.5 (System Development and Demonstration) funding. It supports products successfully developed in the Systems Integration portion of the Systems Development and Demonstration phases through completion of the Milestone C Decision Review. Commercially-off-the-shelf (COTS) medical products are also tested and evaluated for military use, when available. This PE primarily includes pivotal (conclusive) human clinical trials necessary for licensure by the Food and Drug Administration (FDA).

Projects in this PE include the following:

Project 812 funds military relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development focused on military unique needs effecting manning, mobilization, and deployment. Products from this project will normally transition to Department of Defense (DoD) Health Programs or Other Procurement, Army (OPA) Funds.

Project 832 funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. Mature COTS medical products are also evaluated for military use. Consideration will also be given to reduce the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. Products from this project will normally transition to OPA Funds.

Project 849 funds development of candidate medical countermeasures for military relevant infectious diseases. These products fall in four major areas: vaccines, drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. FDA approval is a mandatory obligation for all military products placed into the hands of medical providers or service members for human use. Products from this project will normally transition to DoD Health Programs or OPA funds.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2019 Army	Date: February 2018
---	----------------------------

Appropriation/Budget Activity 2040: Research, Development, Test & Evaluation, Army / BA 5: System Development & Demonstration (SDD)	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev
---	---

Project VS8 program receives products that transition from VS7 and funds effort to complete research and development for the medical evacuation (MEDEVAC) Mission Essential Packages (MEPs) to support 256 Medical Evacuation legacy helicopters. The Army's force design increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs.

These Projects are managed by United States (U.S.) Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the U.S. Army Medical Research and Materiel Command.

B. Program Change Summary (\$ in Millions)	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total
Previous President's Budget	41.124	39.238	45.503	-	45.503
Current President's Budget	36.237	39.238	44.542	-	44.542
Total Adjustments	-4.887	0.000	-0.961	-	-0.961
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-3.506	-			
• SBIR/STTR Transfer	-1.364	-			
• FFRDC Transfer	-0.017	-	-	-	-
• Other Adjustments 2	-	-	-0.961	-	-0.961

Change Summary Explanation

In FY2017 \$3.506 Million was reprogrammed from 0604807A812 to 0603807A811.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army										Date: February 2018		
Appropriation/Budget Activity 2040 / 5					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 812 / Mil HIV Vac&Drug Dev			
COST (\$ in Millions)	Prior Years	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total	FY 2020	FY 2021	FY 2022	FY 2023	Cost To Complete	Total Cost
812: Mil HIV Vac&Drug Dev	-	0.876	1.183	1.179	-	1.179	1.201	1.230	1.067	6.069	0.000	12.805
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
A. Mission Description and Budget Item Justification <p>This Project funds militarily relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development is focused on militarily unique needs effecting manning, mobilization, and deployment.</p> <p>The major contractor is The Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.</p>												
B. Accomplishments/Planned Programs (\$ in Millions)									FY 2017	FY 2018	FY 2019	
Title: Military HIV Vaccine and Drug Development Description: This effort provides funds for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing of vaccines for medical countermeasures to HIV. FY 2018 Plans: Continuing support of Regional vaccine Phase III (large safety and efficacy trial) in sub-Saharan Africa. Will support Global vaccine efficacy studies at multiple international Army-funded study sites. Support entails the performance of later stage Phase II (safety and effectiveness) and Phase III (pivotal effectiveness) clinical trials of selected Global HIV vaccine. FY 2019 Plans: Will continue support of the Global vaccine effectiveness testing effort. This activity is co-funded by the National Institute of Allergy and Infectious Disease (NIAID) and the Bill and Melinda Gates Foundation. This study is anticipated to take 3.5 years to complete. FY 2018 to FY 2019 Increase/Decrease Statement: The slight increase of funding in FY19 is due to inflation factor.									0.876	1.183	1.179	
Accomplishments/Planned Programs Subtotals									0.876	1.183	1.179	
C. Other Program Funding Summary (\$ in Millions) N/A Remarks												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army		Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev	Project (Number/Name) 812 / Mil HIV Vac&Drug Dev
D. Acquisition Strategy Test and evaluate commercially developed vaccine candidates in government-managed trials.		
E. Performance Metrics N/A		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev						Project (Number/Name) 812 / Mil HIV Vac&Drug Dev			
Management Services (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Various : Various	2.634	-		0.211		1.179		-		1.179	Continuing	Continuing	-
Subtotal			2.634	-		0.211		1.179		-		1.179	Continuing	Continuing	N/A
Product Development (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Cost	Various	Henry M. Jackson Foundation, : Various	33.545	-		0.434		-		-		-	Continuing	Continuing	Continuing
Subtotal			33.545	-		0.434		-		-		-	Continuing	Continuing	N/A
Support (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	Various	Various : Various	2.038	-		0.387		-		-		-	Continuing	Continuing	-
Subtotal			2.038	-		0.387		-		-		-	Continuing	Continuing	N/A
Test and Evaluation (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	Various	Henry M. Jackson Foundation, : Various	27.095	0.876		0.151		-		-		-	Continuing	Continuing	Continuing
Subtotal			27.095	0.876		0.151		-		-		-	Continuing	Continuing	N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army										Date: February 2018			
Appropriation/Budget Activity 2040 / 5					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev					Project (Number/Name) 812 / Mil HIV Vac&Drug Dev			
	Prior Years	FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	65.312	0.876		1.183		1.179		-		1.179	Continuing	Continuing	N/A
Remarks													

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2019 Army			Date: February 2018		
Appropriation/Budget Activity 2040 / 5		R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev		Project (Number/Name) 812 / Mil HIV Vac&Drug Dev	

Event Name	FY 2017				FY 2018				FY 2019				FY 2020				FY 2021				FY 2022				FY 2023			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Protein Production of new B/E Protein																												
Phase I Study (small population of healthy volunteers) B/E Protein																												
Phase II prime/boost regional study to confirm safety and evaluate effectiveness																												
Phase III prime/boost regional vaccine in a large well controlled population																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2019 Army			Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	Project (Number/Name) 812 / <i>Mil HIV Vac&Drug Dev</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Protein Production of new B/E Protein	3	2016	2	2019
Phase I Study (small population of healthy volunteers) B/E Protein	2	2017	2	2019
Phase II prime/boost regional study to confirm safety and evaluate effectiveness	2	2018	4	2023
Phase III prime/boost regional vaccine in a large well controlled population	1	2020	4	2021

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army										Date: February 2018		
Appropriation/Budget Activity 2040 / 5					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 832 / Field Medical Systems Engineering Development			
COST (\$ in Millions)	Prior Years	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total	FY 2020	FY 2021	FY 2022	FY 2023	Cost To Complete	Total Cost
832: Field Medical Systems Engineering Development	-	19.733	24.812	28.852	-	28.852	31.484	32.382	31.788	34.048	0.000	203.099
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This Project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. Specifically funds pivotal (conclusive) human clinical trials or mechanical engineering evaluations for effectiveness of devices or biologics (products derived from living organisms) to fulfill unique military requirements. Consideration is also given to reducing the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. This work is frequently completed through a laboratory/contractor team with the contractor obtaining the U.S. FDA licensure for sale of the product.

Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; Se Qual Technologies, Inc.; Enginivity, Inc.; Ultrasound Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Cerdak Ltd; Hemerus Medical, LLC; Fast Track Drugs & Biologics, LLC; Integrated Medical Systems, Inc.; the National Institutes of Health National Heart, Lung and Blood Institute (NHLBI), and the U.S. Army Aeromedical Research Laboratory, Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation. Other military agencies include Program Executive Office (PEO) Soldier, PEO Combat Support/Combat Service Support (CS & CSS), and Naval Undersea Warfare Center.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2017	FY 2018	FY 2019
Title: Field Medical Systems Engineering Development PM Medical Devices	3.029	2.519	2.644
Description: This effort funds the engineering and manufacturing development of medical products for enhanced combat casualty care managed by Program Manager (PM)-Medical Devices.			
FY 2018 Plans: Medical Equipment Sets COTS Modernization of Life Cycle Equipment: Will continue development and testing to ensure the most current and cost effective devices are being utilized. Equipment will be selected for modernization based on its own life cycle plan as part of Sets, Kits and Outfits. Junctional / Noncompressible Hemorrhage Control Agent: Developmental efforts will be completed; available for procurement.			
FY 2019 Plans: Medical Equipment Sets COTS Modernization of Life Cycle Equipment: Will continue development and testing to ensure the most current and cost effective devices are being utilized. Equipment will be selected for modernization based on its own life cycle plan as part of a Sets, Kits and Outfits.			
FY 2018 to FY 2019 Increase/Decrease Statement:			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army		Date: February 2018		
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev	Project (Number/Name) 832 / Field Medical Systems Engineering Development		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2017	FY 2018	FY 2019
Overall funding was increased in FY19 due to payback from earlier FY funding adjustments and approved higher priorities for PM Medical Devices.				
Title: Field Medical Systems Engineering Development PM Pharmaceuticals Description: Funding is provided for engineering and manufacturing development of medical products managed by PM Pharmaceuticals for enhanced combat casualty care and follow-on care, including rehabilitation. FY 2018 Plans: Cryopreserved Platelets: Completing the in-life portion of the Phase 2 safety and effectiveness study in patients with complex cardiac bypass and/or who have an abnormally low amount of platelets. Continuing development of clinical testing protocols for of Phase 3 (expanded safety, effectiveness and dosing) pivotal study. Continuing the manufacturing development and validation of Cryopreserved platelet batches. Freeze-Dried Plasma Program: Based on additional guidance from the FDA, a new Phase 1 dose escalation study that began in FY17 will continue in FY18. Continuing the preparation for a Phase 2 prospective clinical study (safety and efficacy study that follows patients over time to measure progress/outcomes). FY 2019 Plans: Cryopreserved Platelets: Will complete the Phase 2 safety and effectiveness study in patients with complex cardiac bypass and prepare for of Phase 3 (expanded safety, effectiveness and dosing) pivotal study. Will continue the manufacturing development and validation of Cryopreserved platelet batches. Freeze-Dried Plasma Program: Will continue the Phase 2 prospective clinical trial (safety and efficacy trial that follows patients over time to measure progress/outcomes). FY 2018 to FY 2019 Increase/Decrease Statement: Money was shifted from this PM to other PM's to fund higher priority products in the 6.5 PE.		10.052	14.951	14.137
Title: Field Medical Systems Engineering Development PM Medical Support Systems Description: This effort funds the engineering and manufacturing development of medical products managed by PM Medical Support Systems for enhanced combat casualty care and follow-on care, including rehabilitation. FY 2018 Plans: Modernization of medical equipment sets: Evaluate the Field Hospital waste water collection system, vector sampling devices, air sampling products, and other commercial items for medical equipment sets.		6.652	3.456	1.592

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army			Date: February 2018		
Appropriation/Budget Activity 2040 / 5		R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev		Project (Number/Name) 832 / Field Medical Systems Engineering Development	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2017	FY 2018	FY 2019
<p>Airworthiness Testing: Continue to conduct airworthiness testing for Medical Equipment Set and Mission Essential Package with products covering air and ground medical evacuation. Per Army Regulation 70-62, Airworthiness Qualification of Aircraft Systems, all "carry-on" equipment, to include medical devices, must have an Airworthiness Release.</p> <p>Medical Evacuation and Treatment Vehicles Medical Equipment Set and Mission Essential Package and CASEVAC: Continue to collaborate with Program Executive Office Ground Combat Systems for the implementation of the MES and MEP in Initial Operational Test and Evaluation of Armored Multipurpose Vehicle (AMPV). Collaborate with PEO Combat Support/Combat Service Support for implementation of the CASEVAC system for the JLTV.</p> <p>Waste Treatment System for the CSH: Complete development and incorporate changes to the waste treatment system based upon testing for re-test.</p> <p>Improved Flying Vector Trap (IFVT): Collaborate with the Armed Forces Pest Management Board for adoption of the IFVT as a Department of Defense standardized product.</p> <p>Soldier Optimization Decision Aids: Transition the Cold Weather Ensemble Decision Aid and the Heat Strain Decision Aid to Program Executive Office Soldier. Develop and conduct Independent Validation and Verification and limited user testing of the Environmental Hazards App and Mobility Decision Aids.</p> <p>FY 2019 Plans: Modernization of medical equipment sets: Will evaluate blood transport products and other commercial items for medical equipment sets.</p> <p>Airworthiness Testing: Will continue to conduct airworthiness testing, required by AR 70-62, for Medical Equipment Set and Mission Essential Package with products covering air and ground medical evacuation.</p> <p>Medical Evacuation and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Will continue to collaborate with Program Executive Office Ground Combat Systems (PEO GCS) for the implementation of the Medical Equipment Set and Mission Essential Package and user evaluations of the Armored Multipurpose Vehicle.</p> <p>Waste Treatment System for the CSH: Testing of waste Treatment System for the CSH.</p> <p>Soldier Optimization Decision Aids: Coordinate with PEO Soldier to transition the Environment Health Assessment and Risk Management (EHARM) tool.</p>					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army		Date: February 2018	
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev	Project (Number/Name) 832 / Field Medical Systems Engineering Development	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2017	FY 2018
Remote Triage Sensor System: Testing the Remote Triage Sensor System.			
FY 2018 to FY 2019 Increase/Decrease Statement: Money was shifted from this PM to other PM's to fund higher priority products in the 6.5 PE .			
Title: Field Medical Systems Engineering Development -PM Neurotrauma & Psychological Health Description: This effort funds systems engineering development of medical products managed by Program Manager Neurotrauma & Psychological Health for enhanced combat casualty care and follow-on care, including rehabilitation. FY 2018 Plans: Laboratory Assay for Traumatic Brain Injury (TBI) (formerly TBI Diagnostic Assay System) Increment II Point of Care Device: Finalizing the Biomarker and Platform technologies and combine the technologies into one system to conduct validation studies. FY 2019 Plans: Laboratory Assay for TBI (formerly TBI Diagnostic Assay System) Increment II Point of Care Device: Will begin required validation studies. FY 2018 to FY 2019 Increase/Decrease Statement: Overall funding to the PE was increased from FY18 to FY19 and funds were programmed to this PM to fund the planned progression of the development of a TBI assay and the FDA requirements for clinical trials for this product.		-	3.886
Accomplishments/Planned Programs Subtotals		19.733	28.852
C. Other Program Funding Summary (\$ in Millions) N/A			
Remarks			
D. Acquisition Strategy Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
E. Performance Metrics N/A			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev						Project (Number/Name) 832 / Field Medical Systems Engineering Development			
Management Services (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Various : Various	32.069	2.521		3.724		3.172		-		3.172	Continuing	Continuing	Continuing
Subtotal			32.069	2.521		3.724		3.172		-		3.172	Continuing	Continuing	N/A
Product Development (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Freeze-dried Human Plasma	Various	HemCon Medical Technologies, Inc. : Tigard OR	32.783	-		-		-		-		-	Continuing	Continuing	Continuing
Hypertonic Saline Dextran	Various	National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) : Various	15.100	-		-		-		-		-	Continuing	Continuing	Continuing
Medical Product Development Cost	Various	Various : Various	6.270	-		2.206		2.565		-		2.565	Continuing	Continuing	Continuing
Extended Life Red Blood Cell Product	Various	Hemerus Medical, LLC, : Various	3.140	-		-		-		-		-	Continuing	Continuing	Continuing
Cryopreserved Platelets	Various	Clinical Research Management, Inc : Hinckley, OH	3.293	0.980		4.417		2.640		-		2.640	Continuing	Continuing	Continuing
Cryopreserved Platelets	Various	Multiple DoD activities and Dartmouth Hitchcock Med Ctr : North Potomac, MD	14.362	-		-		-		-		-	Continuing	Continuing	Continuing
Cryopreserved Platelets	Various	TBD : TBD	1.875	-		-		-		-		-	0.000	1.875	-
Intracellular Hemorrhage Treatment	TBD	TBD : TBD	0.600	-		-		-		-		-	0.000	0.600	-

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 832 / Field Medical Systems Engineering Development					
Product Development (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
TBI Diagnostic Assay System - Increment II (benchtop/POC/ Bandits)	Various	Banyan BioMarkers, Inc : Alachua, FL	0.373	-		-		-		-		-	0.000	0.373	-
Noninvasive Neurodiagnostics	TBD	TBD : TBD	2.647	-		-		-		-		-	0.000	2.647	-
Impedance Threshold Device for the Treatment of Traumatic Brain Injury	TBD	Advance Circulatory Systems Inc. : Roseville, MN	4.387	-		-		-		-		-	0.000	4.387	-
Pre-Hospital Medical Informatics Transport (Ground Transport Telemedicine)	TBD	TBD : TBD	2.116	4.205		-		-		-		-	0.000	6.321	-
Advanced wound care	Various	TBD : TBD	-	1.230		-		-		-		-	0.000	1.230	-
Junction Noncompressible Hemorrhage	TBD	RevMedX Inc : Wilsonville OR	-	1.805		-		-		-		-	0.000	1.805	-
Laboratory Assay for Traumatic Brain Injury	C/Various	Abbott Laboratories : Chicago, IL	-	-		3.910		10.534		-		10.534	Continuing	Continuing	Continuing
Subtotal			86.946	8.220		10.533		15.739		-		15.739	Continuing	Continuing	N/A
Support (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Regulatory Support	Various	Clinical Research Management, Inc., : Various	6.523	1.520		0.307		0.332		-		0.332	Continuing	Continuing	Continuing
Medical Product Development Support Cost	Various	Various : Various	10.209	-		1.829		-		-		-	Continuing	Continuing	Continuing
Medical Equipment Sets Development	Various	Various : Various	2.670	-		-		-		-		-	0.000	2.670	-
Subtotal			19.402	1.520		2.136		0.332		-		0.332	Continuing	Continuing	N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 832 / Field Medical Systems Engineering Development					
Test and Evaluation (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	Various	Various : Various	16.023	-		1.481		-		-		-	Continuing	Continuing	Continuing
Cryopreserved Platelets	TBD	TBD : TBD	8.994	4.125		3.260		5.639		-		5.639	0.000	22.018	-
Medical Equipment Sets Development	Various	Various : Various	1.206	-		0.650		3.970		-		3.970	0.000	5.826	-
Freeze Dried Plasma	C/CPFF	TBD : TBD	6.725	3.347		3.028		-		-		-	0.000	13.100	-
Subtotal			32.948	7.472		8.419		9.609		-		9.609	Continuing	Continuing	N/A
			Prior Years	FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			171.365	19.733		24.812		28.852		-		28.852	Continuing	Continuing	N/A
Remarks															

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2019 Army			Date: February 2018		
Appropriation/Budget Activity 2040 / 5		R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev		Project (Number/Name) 832 / Field Medical Systems Engineering Development	

Event Name	FY 2017				FY 2018				FY 2019				FY 2020				FY 2021				FY 2022				FY 2023			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Cryopreserved Platelets (CPP) Phase 2 efficacy clinical studies																												
Cryopreserved Platelets (CPP) Phase III clinical studies																												
Cryopreserved Platelets (CPP) Milestone C																												
Freeze-dried Plasma (FDP) Phase I safety clinical studies																												
FDP Phase 2 efficacy clinical studies																												
FDP MS-C																												
Laboratory Assay for TBI Increment II Point of Care Device Clinical Trial																												
Laboratory Assay for TBI Point of Care Device MS C																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2019 Army			Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	Project (Number/Name) 832 / <i>Field Medical Systems Engineering Development</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Cryopreserved Platelets (CPP) Phase 2 efficacy clinical studies	3	2015	4	2018
Cryopreserved Platelets (CPP) Phase III clinical studies	4	2017	3	2021
Cryopreserved Platelets (CPP) Milestone C	2	2020	2	2020
Freeze-dried Plasma (FDP) Phase I safety clinical studies	3	2014	2	2018
FDP Phase 2 efficacy clinical studies	2	2016	2	2019
FDP MS-C	4	2020	4	2020
Laboratory Assay for TBI Increment !! Point of Care Device Clinical Trial	1	2020	4	2021
Laboratory Assay for TBI Point of Care Device MS C	1	2023	1	2023

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army										Date: February 2018		
Appropriation/Budget Activity 2040 / 5					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 849 / Infec Dis Drug/Vacc Ed			
COST (\$ in Millions)	Prior Years	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total	FY 2020	FY 2021	FY 2022	FY 2023	Cost To Complete	Total Cost
849: Infec Dis Drug/Vacc Ed	-	15.520	13.243	14.511	-	14.511	15.980	16.410	16.880	17.181	0.000	109.725
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
A. Mission Description and Budget Item Justification												
<p>This Project funds development of candidate medical countermeasures (MCM: e.g. vaccines, drugs, diagnostic kits/devices) for militarily relevant infectious diseases. This also funds methods to determine if insects are infected with pathogenic organisms thereby posing a risk to service members' and control insect exposure/prevent Warfighters from being bitten by those insects. It funds research that supports conclusive human clinical trials to demonstrate MCM effectiveness safety and related manufacturing tests. This work, which is jointly performed by military laboratories, civilian contracted pharmaceutical firms and foreign research partners, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. Medical products approved for human use must meet the U.S. FDA approval before MCM can be used on Warfighters. Development priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development, production, and sustainment). Malaria, dysentery, hepatitis , and Dengue diseases (a severe debilitating disease transmitted by mosquitoes), which are found in all Combatant Command areas and are at the top of the infectious diseases risks list.</p>												
B. Accomplishments/Planned Programs (\$ in Millions)									FY 2017	FY 2018	FY 2019	
Title: Infectious Disease Drug and Vaccine Engineering Development									15.520	13.243	14.511	
Description: Funding for research and development efforts for Drugs and Vaccines.												
FY 2018 Plans:												
Dengue Tetravalent Vaccine (DTV): Fund Block I Dengue Tetravalent Vaccine through FY18 to complete two-year study subject follow-up required by Thai Ministry of Public Health. Continue military-specific clinical trials that begin in FY17.												
Next Generation Malaria Prophylaxis: Continue to complete New Drug Application preparatory work for filing with the FDA. Continue the retinal (eye) safety study started in FY16 and prepare the protocols for required soldier specific studies.												
Topical Antileishmanial Cream (TLC, Paromomycin/Gentamicin): Conduct stability testing of the registration lots of the drug product. Prepare for potential FDA requirements for post-marketing surveillance or clinical trials to gather additional information about a product's safety, effectiveness, or optimal use.												
Antimalarial Drug, Artesunate Intravenous: Support the FDA's inquiries during the review process of the New Drug Application. Work with the commercial partner to support commercial marketing and distribution plans for the drug.												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army		Date: February 2018		
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev	Project (Number/Name) 849 / Infec Dis Drug/Vacc Ed		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2017	FY 2018	FY 2019
Dengue Vaccine Block II: Continue development of additional dengue human challenge strains. Evaluate vaccine candidates using dengue human challenge studies in preparation for pivotal safety, effectiveness, and dosing (Phase III) clinical trials.				
Rapid Diagnostic and Detection Devices (Infectious Disease Diagnostics (Multiple)): Continue field testing and evaluation of several product candidates to include: dengue and chikungunya.				
FY 2019 Plans: Dengue Tetravalent Vaccine (DTV): Continue to fund Advance Development (AD) candidate vaccine as it enters third year of pivotal phase 3 clinical trial.				
Next Generation Malaria Prophylaxis: Will continue the retinal (eye) safety study (3 year study) started in FY17. Address any FDA post-marketing approval requirements.				
Topical Antileishmanial Cream (TLC, Paromomycin/Gentamicin): The planned submission of the Non-Disclosure Agreement (NDA) did not occur in FY17 due to additional testing requirements by the FDA to demonstrate therapeutic equivalence of pre- and post-manufacturing change drug product. The NDA package will be completed and submitted to the FDA for approval in FY19. The manufacturing process will be validated in preparation for commercial production of the drug product.				
Antimalarial Drug, Artesunate Intravenous: Will support the FDA's inquiries during the review process of the New Drug Application. Will complete required non-clinical study for FDA review.				
Dengue Vaccine Block II: Will continue the development, testing and selection of strains for the dengue human infection model (DHIM) to be used in the early evaluation of dengue vaccine candidates in advance of phase 2 and 3 trials.				
Rapid Diagnostic and Detection Devices (Infectious Disease Diagnostics (Multiple)): The dengue and chikungunya assays will continue to be developed and evaluated. Clinical testing will be conducted for dengue and clinical sites identified for chikungunya.				
FY 2018 to FY 2019 Increase/Decrease Statement: The increase of funding in FY19 is due to the planned progression of multiple infectious disease medical products in development. Funding will support the FDA requirements for clinical trials for those products.				
Accomplishments/Planned Programs Subtotals				
C. Other Program Funding Summary (\$ in Millions)				
N/A				

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army		Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev	Project (Number/Name) 849 / Infec Dis Drug/Vacc Ed
C. Other Program Funding Summary (\$ in Millions)		
Remarks		
D. Acquisition Strategy Test and evaluate in-house and commercially developed products in government-managed trials to meet FDA requirements and Environmental Protection Agency registration.		
E. Performance Metrics N/A		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) 849 / Infec Dis Drug/Vacc Ed					
Management Services (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Various : Various	19.873	0.989		0.877		0.927		-		0.927	Continuing	Continuing	Continuing
Medical Product Development Management Services Cost	C/CPFF	General Dynamics Information Technology : Frederick MD	3.768	3.012		3.212		2.849		-		2.849	0.000	12.841	-
Subtotal			23.641	4.001		4.089		3.776		-		3.776	Continuing	Continuing	N/A
Product Development (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Cost	Various	Various : Various	36.051	1.504		0.963		1.744		-		1.744	Continuing	Continuing	Continuing
Topical Antileishmanial Drug	TBD	TBD : TBD	2.400	-		-		-		-		-	0.000	2.400	-
Topical Antileishmanial Drug	C/TBD	Advantar Laboratories, INC : TBD	1.891	0.316		0.586		-		-		-	0.000	2.793	-
Dengue Tetravalent Vaccine	TBD	TBD : TBD	2.047	-		-		-		-		-	0.000	2.047	-
Hemorrhagic Fever W/ Renal Syndrome	C/TBD	TBD : TBD	1.000	-		-		-		-		-	0.000	1.000	-
Subtotal			43.389	1.820		1.549		1.744		-		1.744	Continuing	Continuing	N/A
Support (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	Various	Various : Various	19.380	-		-		0.157		-		0.157	Continuing	Continuing	Continuing

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev						Project (Number/Name) 849 / Infec Dis Drug/Vacc Ed			
Support (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	PO	Clinical Research Management, In : Hinckley, OH	3.455	1.952		0.976		-		-		-	0.000	6.383	-
Subtotal			22.835	1.952		0.976		0.157		-		0.157	Continuing	Continuing	N/A
Test and Evaluation (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	Various	Various : Various	41.721	4.639		4.067		0.895		-		0.895	Continuing	Continuing	Continuing
Dengue Tetravalent Vaccine	TBD	WRAIR/AFRIMS : Silver Spring MD	-	0.952		0.450		0.594		-		0.594	0.000	1.996	-
Dengue Tetravalent Vaccine	C/TBD	TBD : TBD	-	2.156		2.112		1.151		-		1.151	0.000	5.419	-
Product Development of Dengue Tetravalent Vaccine	Various	TBD : TBD	4.530	-		-		-		-		-	0.000	4.530	-
Next Generation Malaria Prophylaxis	C/Various	TBD : TBD	-	-		-		3.561		-		3.561	0.000	3.561	-
Dengue Vaccine block II	C/Various	TBD : TBD	-	-		-		2.633		-		2.633	0.000	2.633	-
Subtotal			46.251	7.747		6.629		8.834		-		8.834	Continuing	Continuing	N/A
			Prior Years	FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			136.116	15.520		13.243		14.511		-		14.511	Continuing	Continuing	N/A
Remarks															

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2019 Army

Date: February 2018

Appropriation/Budget Activity

2040 / 5

R-1 Program Element (Number/Name)

PE 0604807A / Medical Materiel/Medical
Biological Defense Equipment - Eng Dev

Project (Number/Name)

849 / Infec Dis Drug/Vacc Ed

Event Name	FY 2017				FY 2018				FY 2019				FY 2020				FY 2021				FY 2022				FY 2023			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Dengue Tetravalent Vaccine (DTV) Phase 3 Pivotal Clinical Trials	FY11-FY18																											
DTV Milestone C (MS-C) Engineering, Manufacturing and Development phase review																												
DTV Biologic Licensing Application (BLA) Submission																												
DTV BLA Approval																												
Malaria Prophylaxis (MS-C) Engineering, Manufacturing and Development phase																												
Paromomycin/Gentamicin TLC Phase 3 Safety and Effectiveness Clinical Trial																												
Paromomycin/Gentamicin TLC (MS-C) Engineering, Manufacturing and Development																												
Paromomycin/Gentamicin TLC New Drug Application (NDA)																												
Paromomycin/Gentamicin TLC FDA Approval																												
Paromomycin/Gentamicin TLC (Fielding / Delivery)																												
Leishmania Rapid Diagnostic Device (Fielding / Delivery)																												
Dengue Vaccine Block II Adult Indication Studies																												
Dengue Vaccine Block II OCONUS Clinical Trials																												

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2019 Army

Date: February 2018

[illegible]

2040 / 5

[illegible]

PE 0604807A / Medical Materiel/Medical
Biological Defense Equipment - Eng Dev

Project (Number/Name)	Start Date	End Date	Duration (Days)	Progress (%)	Status	Notes
101	2023-01-01	2023-01-15	14	100	Completed	Project 101 completed on time.
102	2023-01-15	2023-02-01	16	75	In Progress	Project 102 is 75% complete.
103	2023-02-01	2023-02-15	14	50	In Progress	Project 103 is 50% complete.
104	2023-02-15	2023-03-01	15	25	In Progress	Project 104 is 25% complete.
105	2023-03-01	2023-03-15	14	10	In Progress	Project 105 is 10% complete.
106	2023-03-15	2023-03-31	15	0	Not Started	Project 106 has not started yet.
107	2023-03-31	2023-04-15	15	0	Not Started	Project 107 has not started yet.
108	2023-04-15	2023-04-30	15	0	Not Started	Project 108 has not started yet.
109	2023-04-30	2023-05-15	15	0	Not Started	Project 109 has not started yet.
110	2023-05-15	2023-05-31	15	0	Not Started	Project 110 has not started yet.

849 / *Infec Dis Drug/Vacc Ed*[illegible]

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2019 Army			Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	Project (Number/Name) 849 / <i>Infec Dis Drug/Vacc Ed</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Dengue Tetravalent Vaccine (DTV) Phase 3 Pivotal Clinical Trials	1	2011	2	2019
DTV Milestone C (MS-C) Engineering, Manufacturing and Development phase review	1	2021	1	2021
DTV Biologic Licensing Application (BLA) Submission	2	2020	2	2020
DTV BLA Approval	2	2021	2	2021
Malaria Prophylaxis (MS-C) Engineering, Manufacturing and Development phase	4	2017	4	2017
Paromomycin/Gentamicin TLC Phase 3 Safety and Effectiveness Clinical Trial	1	2016	1	2017
Paromomycin/Gentamicin TLC (MS-C) Engineering, Manufacturing and Development	2	2018	2	2018
Paromomycin/Gentamicin TLC New Drug Application (NDA)	3	2017	3	2017
Paromomycin/Gentamicin TLC FDA Approval	4	2018	4	2018
Paromomycin/Gentamicin TLC (Fielding / Delivery)	4	2018	4	2020
Leishmania Rapid Diagnostic Device (Fielding / Delivery)	1	2015	4	2020
Dengue Vaccine Block II Adult Indication Studies	1	2016	4	2020
Dengue Vaccine Block II OCONUS Clinical Trials	1	2016	4	2020
Topical Antileishmanial Cream (Paromomycin/Gentamicin, TLC) MS-C	2	2019	2	2019

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2019 Army										Date: February 2018		
Appropriation/Budget Activity 2040 / 5					R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev				Project (Number/Name) VS8 / MEDEVAC Mission Equipment Package (MEP) - End Dev			
COST (\$ in Millions)	Prior Years	FY 2017	FY 2018	FY 2019 Base	FY 2019 OCO	FY 2019 Total	FY 2020	FY 2021	FY 2022	FY 2023	Cost To Complete	Total Cost
VS8: MEDEVAC Mission Equipment Package (MEP) - End Dev	-	0.108	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	0.108
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
A. Mission Description and Budget Item Justification <p>Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high U.S. troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009, a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the Army Medical Department (AMEDD) accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP upgrades and retrofits the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.</p>												
B. Accomplishments/Planned Programs (\$ in Millions)										FY 2017	FY 2018	FY 2019
Title: Interim MEDEVAC Mission Support System (IMMSS)										0.108	-	-
Description: Interim MEDEVAC Mission Support System (IMMSS) - Patient Handling System for safely handling patient through a system of seats, patient litters etc.												
Accomplishments/Planned Programs Subtotals										0.108	-	-
C. Other Program Funding Summary (\$ in Millions) N/A Remarks D. Acquisition Strategy Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding. E. Performance Metrics N/A												

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2019 Army												Date: February 2018			
Appropriation/Budget Activity 2040 / 5						R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev						Project (Number/Name) VS8 / MEDEVAC Mission Equipment Package (MEP) - End Dev			
Product Development (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MEDEVAC Mission Sensor Forward Looking Infrared	TBD	Redstone Arsenal, : AL	2.104	-		-		-		-		-	0.000	2.104	-
Subtotal			2.104	-		-		-		-		-	0.000	2.104	N/A
Support (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	SS/UCA	Redstone Arsenal : AL	0.621	-		-		-		-		-	0.000	0.621	-
Subtotal			0.621	-		-		-		-		-	0.000	0.621	N/A
Test and Evaluation (\$ in Millions)				FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
IMMSS test and evaluation	TBD	Redstone Arsenal : AL	-	0.108		-		-		-		-	0.000	0.108	-
Subtotal			-	0.108		-		-		-		-	0.000	0.108	N/A
			Prior Years	FY 2017		FY 2018		FY 2019 Base		FY 2019 OCO		FY 2019 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			2.725	0.108		0.000		-		-		-	0.000	2.833	N/A
Remarks															

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2019 Army																Date: February 2018																					
Appropriation/Budget Activity 2040 / 5										R-1 Program Element (Number/Name) PE 0604807A / Medical Materiel/Medical Biological Defense Equipment - Eng Dev								Project (Number/Name) VS8 / MEDEVAC Mission Equipment Package (MEP) - End Dev																			
Event Name										FY 2017				FY 2018				FY 2019				FY 2020				FY 2021				FY 2022				FY 2023			
										1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
IMMSS (Interim MEDEVAC Mission Support System)										[REDACTED]				Modifications to IMMSS due to new skills																							

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2019 Army			Date: February 2018
Appropriation/Budget Activity 2040 / 5	R-1 Program Element (Number/Name) PE 0604807A / <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	Project (Number/Name) VS8 / <i>MEDEVAC Mission Equipment Package (MEP) - End Dev</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
IMMSS (Interim MEDEVAC Mission Support System)	1	2016	4	2017

Note

Modifications to IMMSS based on new approved paramedic skills for medical personnel